Filing Details

 

 

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

 

Syros Pharmaceuticals, Inc. (the "Issuer").

 

 

 

8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631

 

 

 

87184Q107

 

Not Applicable.

 

(a)

Amount beneficially owned:

 

(b)

Percent of class:

 

 

 

Item 10.

Certification

 

 

 

	By:                    *
	Keith Crandell
	Managing Director

 

 

 

	*
	Keith Crandell

This Amendment No. 3 to Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2 and incorporated herein by reference.

Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Syros Therapeutics, Inc.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

 

 

 

	ARCH VENTURE PARTNERS VII, L.P.
	By:   ARCH Venture Partners VII, LLC
	its General Partner

 

	*
	Keith Crandell

This Agreement was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2 and incorporated herein by reference.

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof.

 

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 7^th day of May, 2013.

 

 

 

	ARCH VENTURE PARTNERS VII, L.P.
	By:   ARCH Venture Partners VII, LLC
	its General Partner

 

	/s/ Keith Crandell
	Keith Crandell